Favrille, Inc. (NASDAQ:FVRL) fell 85% today, shares are now only 25 cents after the Biopharmaceutical said it will end development of Specifid, after the drug failed to prove effective against non-Hodgkin’s lymphoma in a late-stage trial.  Major swing, and a miss.

More from Forbes.com:

Favrille (nasdaq: FVRL) said patients taking Specifid and Bayer (nyse: BAY) AG’s Leukine did not show slower progression of the immune system cancer than patients taking Leukine and a placebo. All patients in the trial had previously taken Genentech (nyse: DNA)’s Rituxan.

“We are clearly very disappointed with the data from this trial,” said John P. Longenecker, president and chief executive of Favrille, in a statement. “Based on these results, we are discontinuing development of Specifid and are currently evaluating steps to conserve cash and recognize value on our assets.”

Masters, think twice if you think there’s a bounce play in this stock, you can’t bounce a dead cat.

Last 5 posts by Ben Stevens

• WaMu (WM) down to $3.60, Kerry you're Fired - September 8th, 2008
• Coal not so cool today: Arch Coal, Peabody fall hard (ACI, BTU) - September 2nd, 2008
• Another blow to the already beat down Whole Foods (WFMI) - August 10th, 2008
• $7 Buys you a pillow but not one share of JetBlue (JBLU) - August 4th, 2008
• AMD: Finally worth a look - July 19th, 2008